血液系统恶性肿瘤中去甲基化药物的应用：治疗偏好与结果
The use of hypomethylating agents in hematologic malignancies: treatment preferences and results.
作者信息
Serin Istemi, Dogu Mehmet Hilmi
机构信息
University of Health Science, Istanbul Training & Research Hospital, Department of Hematology, Istanbul, Turkey.
Istinye University, Department of Internal Medicine and Hematology, Liv Hospital Ulus, Beşiktaş, Turkey.
出版信息
Int J Hematol Oncol. 2021 Nov 12;10(4):IJH37. doi: 10.2217/ijh-2020-0019. eCollection 2021 Dec.
AIM
The objective of this article was to compare the efficiency of azacitidine (AZA) and decitabine (DAC) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not suitable for high-dose chemotherapy.
MATERIALS AND METHODS
MDS and AML patients who were treated with hypomethylating agents (HMAs) between January 2005 and 2020 were evaluated retrospectively.
RESULTS
No statistically significant difference was found between the patients who received AZA or DAC in AML patients. In MDS group, the rate of patients who achieved remission was statistically significantly higher in patients who received DAC (p = 0.032).
CONCLUSION
The advantage in terms of response for MDS and no survival difference between AZA and DAC for AML and MDS patients will be an important contribution to the literature.
目的
本文旨在比较阿扎胞苷（AZA）和地西他滨（DAC）对不适于大剂量化疗的骨髓增生异常综合征（MDS）和急性髓系白血病（AML）患者的疗效。
材料与方法
回顾性评估2005年1月至2020年期间接受去甲基化药物（HMAs）治疗的MDS和AML患者。
结果
在AML患者中，接受AZA或DAC治疗的患者之间未发现统计学上的显著差异。在MDS组中，接受DAC治疗的患者缓解率在统计学上显著更高（p = 0.032）。
结论
MDS在反应方面的优势以及AZA和DAC对AML和MDS患者在生存方面无差异，将对文献做出重要贡献。
Zotero 插件